492 filings
Page 21 of 25
8-K
77pyn3 44xa
1 Apr 19
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
4:08pm
8-K
kebk0bq1ffj3si
25 Mar 19
Other Events
4:45pm
4
o871 cad8
18 Mar 19
BioXcel Therapeutics / Michal Votruba ownership change
5:38pm
3
1ur9u3ylqmi5o3ex
18 Mar 19
BioXcel Therapeutics / Michal Votruba ownership change
5:35pm
S-3
kx03 djvgejasa
14 Mar 19
Shelf registration
4:45pm
8-K
a6fnyr6c
12 Mar 19
Other Events
5:21pm
10-K
0kw4doymxaqv4k
12 Mar 19
Annual report
12:00am
8-K
ymwxw
11 Mar 19
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
4:38pm
8-K
n2ifg0p1
7 Mar 19
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
4:42pm
8-K
t7mw8g9
4 Mar 19
Other Events
4:19pm
SC 13G
8emywqj2
14 Feb 19
BioXcel Therapeutics, Inc.
7:33am
8-K
c7ba30wf1 ui
11 Feb 19
Regulation FD Disclosure
4:47pm
8-K
gqv6ym4qu81ojm7bp
4 Feb 19
Other Events
5:03pm
SC 13G/A
gsxu3jz8 b6
10 Jan 19
BioXcel Therapeutics, Inc.
4:27pm
8-K
6p1hmwktncv0ffbj27
3 Jan 19
Regulation FD Disclosure
4:16pm
8-K
7ees85 1v1uo5
27 Dec 18
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
4:11pm
8-K
hbzk0
20 Dec 18
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
5:08pm
CT ORDER
ap0 8a5fzozosiedwk
20 Dec 18
Confidential treatment order
11:56am
4
v63uv
14 Dec 18
BioXcel Therapeutics / Vimal Mehta ownership change
4:30pm
8-K
d5egqf69u
12 Dec 18
Regulation FD Disclosure
4:11pm